



ACCELERATING MALARIA VACCINE DEVELOPMENT

Developing malaria vaccines: Investing in the tools of the trade

[Read more »](#)




Photo credit: Paul Quinlan

PARTNERING WITH US

We are pursuing a range of vaccine

OUR PORTFOLIO

We maintain a

Project name	Lead organization	Start date	End date

News and announcements

MVI collaborates with International AIDS Vaccine Initiative and Imperial College London

New central "reference" lab to standardize ability to measure performance of malaria vaccine formulations.

MVI names eminent malaria scientists and vaccinologists to advisory council

MVI welcomes new members to its Vaccine Science Portfolio Advisory Council.

MVI collaborates with National Institute of Allergy and Infectious Diseases and Johns Hopkins

Partnership to evaluate potential vaccine candidate designed to prevent malaria transmission from mosquitoes to humans.

Of note

development approaches with an expanding circle of industry, academic, and government partners.

- [Our approach »](#)
- [Partnering with us »](#)
- [Contribute to PATH »](#)

diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.




[View the portfolio »](#)

WHAT WE DO AND HOW WE DO IT

We provide funding and technical support to partners worldwide to accelerate the development of malaria vaccines. We also work to ensure that malaria vaccines will reach those who need them.

[Read more »](#)



Introduction to MVI's director, Dr. David Kaslow



Conferences and events



RTS,S trial sites and first results of Phase 3 trial



SIGN UP
for our e-newsletter

Follow us:  [Twitter](#)  [Flickr](#)

[Home](#) | [Privacy policy](#) | [Copyright policy](#) | [Jobs at PATH website](#)

© 1995–2012, PATH.

